Clinical Trial Update: Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 [Phase 1, Phase 2]

View source ↗

Summary

A long-term follow-up study of AUR-201 implanted in unilateral microtia patients (Phase 1/2) sponsored by Auregen Biotherapeutics has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microtia

Drugs mentioned

• AUR-201

Snippet

Sponsor: Auregen Biotherapeutics, SA | Conditions: Microtia | Phase 1, Phase 2 | Status: TERMINATED